Unravelling the mechanism of action of NS9283, a positive allosteric modulator of (α4)3(β2)2 nicotinic ACh receptors

British Journal of Pharmacology

Volumn 168, Issue 8, 2013, Pages 2000-2010

  Grupe, M ^a,b   Jensen, A A ^b   Ahring, P K ^a   Christensen, J K ^a,c   Grunnet, M ^a,d  

^a NEUROSEARCH A S   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Area9   (Denmark)

^d H LUNDBECK A S   (Denmark)

Author keywords

nicotinic ACh receptor; NS9283; patch clamp; positive allosteric modulator; 4 2

Indexed keywords

3 [3 (3 PYRIDYL) 1,2,4 OXADIAZOL 5 YL]BENZONITRILE; 4 AMINOBUTYRIC ACID A RECEPTOR; NICOTINIC AGENT; NICOTINIC RECEPTOR ALPHA4BETA2; NS 9283; UNCLASSIFIED DRUG; 3-(3-(PYRIDINE-3-YL)-1,2,4-OXADIAZOL-5-YL)BENZONITRILE; ACETYLCHOLINE; NICOTINIC RECEPTOR; OXADIAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ARTICLE; CONTROLLED STUDY; DESENSITIZATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; ENZYME INACTIVATION; ENZYME KINETICS; HUMAN; HUMAN CELL; IONIC STRENGTH; PATCH CLAMP; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOICHIOMETRY; HEK293 CELL LINE; METABOLISM; PATCH CLAMP TECHNIQUE;

ACETYLCHOLINE; DRUG SYNERGISM; HEK293 CELLS; HUMANS; NICOTINIC AGONISTS; OXADIAZOLES; PATCH-CLAMP TECHNIQUES; PYRIDINES; RECEPTORS, NICOTINIC;

EID: 84875466730     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12095     Document Type: Article

References (53)

1. Albrecht BK, Berry V, Boezio AA, Cao L, Clarkin K, Guo W, et al. (2008). Discovery and optimization of substituted piperidines as potent, selective, CNS-penetrant alpha4beta2 nicotinic acetylcholine receptor potentiators. Bioorg Med Chem Lett 18: 5209-5212.
2. Alexander SP, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
3. Apostol G, Abi-Saab W, Kratochvil CJ, Adler LA, Robieson WZ, Gault LM, et al. (2012). Efficacy and safety of the novel alphabeta neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study. Psychopharmacology 219: 715-725.
4. Arai A, Lynch G, (1998). The waveform of synaptic transmission at hippocampal synapses is not determined by AMPA receptor desensitization. Brain Res 799: 230-234.
5. A receptor channels. J Neurosci 21: 9083-9091.
6. A) receptor opening frequency depends on activation context: a patch clamp and simulation study. Epilepsy Res 85: 212-220.
7. Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, et al. (2005). Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 48: 3474-3477.
8. daCosta CJ, Free CR, Corradi J, Bouzat C, Sine SM, (2011). Single-channel and structural foundations of neuronal alpha7 acetylcholine receptor potentiation. J Neurosci 31: 13870-13879.
9. Dinklo T, Shaban H, Thuring JW, Lavreysen H, Stevens KE, Zheng L, et al. (2011). Characterization of 2-[ [4-fluoro-3-(trifluoromethyl)phenyl]amino]-4-(4- pyridinyl)-5-thiazoleme thanol (JNJ-1930942), a novel positive allosteric modulator of the {alpha}7 nicotinic acetylcholine receptor. J Pharmacol Exp Ther 336: 560-574.
10. A) receptors. Neuroreport 10: 817-821.
11. Giniatullin R, Nistri A, Yakel JL, (2005). Desensitization of nicotinic ACh receptors: shaping cholinergic signaling. Trends Neurosci 28: 371-378.
12. Gotti C, Zoli M, Clementi F, (2006). Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trends Pharmacol Sci 27: 482-491.
13. Gotti C, Moretti M, Meinerz NM, Clementi F, Gaimarri A, Collins AC, et al. (2008). Partial deletion of the nicotinic cholinergic receptor alpha 4 or beta 2 subunit genes changes the acetylcholine sensitivity of receptor-mediated 86Rb+ efflux in cortex and thalamus and alters relative expression of alpha 4 and beta 2 subunits. Mol Pharmacol 73: 1796-1807.
14. Gronlien JH, Hakerud M, Ween H, Thorin-Hagene K, Briggs CA, Gopalakrishnan M, et al. (2007). Distinct profiles of alpha7 nAChR positive allosteric modulation revealed by structurally diverse chemotypes. Mol Pharmacol 72: 715-724.
15. Harpsøe K, Ahring PK, Christensen JK, Jensen ML, Peters D, Balle T, (2011). Unraveling the high- and low-sensitivity agonist responses of nicotinic acetylcholine receptors. J Neurosci 31: 10759-10766.
16. Haydar SN, Dunlop J, (2010). Neuronal nicotinic acetylcholine receptors-targets for the development of drugs to treat cognitive impairment associated with schizophrenia and Alzheimer's disease. Curr Top Med Chem 10: 144-152.
17. Hill MW, Reddy PA, Covey DF, Rothman SM, (1998). Contribution of subsaturating GABA concentrations to IPSCs in cultured hippocampal neurons. J Neurosci 18: 5103-5111.
18. Howe WM, Ji J, Parikh V, Williams S, Mocaer E, Trocme-Thibierge C, et al. (2010). Enhancement of attentional performance by selective stimulation of alpha4beta2(*) nAChRs: underlying cholinergic mechanisms. Neuropsychopharmacology 35: 1391-1401.
19. Hurst RS, Hajos M, Raggenbass M, Wall TM, Higdon NR, Lawson JA, et al. (2005). A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization. J Neurosci 25: 4396-4405.
20. Jin R, Clark S, Weeks AM, Dudman JT, Gouaux E, Partin KM, (2005). Mechanism of positive allosteric modulators acting on AMPA receptors. J Neurosci 25: 9027-9036.
21. Katz B, Thesleff S, (1957). A study of the desensitization produced by acetylcholine at the motor end-plate. J Physiol 138: 63-80.
22. Lee CH, Zhu C, Malysz J, Campbell T, Shaughnessy T, Honore P, et al. (2011). alpha4beta2 neuronal nicotinic receptor positive allosteric modulation: an approach for improving the therapeutic index of alpha4beta2 nAChR agonists in pain. Biochem Pharmacol 82: 959-966.
23. Lester RA, (2004). Activation and desensitization of heteromeric neuronal nicotinic receptors: implications for non-synaptic transmission. Bioorg Med Chem Lett 14: 1897-1900.
24. A receptor channels. Annu Rev Neurosci 17: 569-602.
25. A receptor channels. Ion Channels 3: 315-343.
26. Malysz J, Gronlien JH, Anderson DJ, Hakerud M, Thorin-Hagene K, Ween H, et al. (2009). In vitro pharmacological characterization of a novel allosteric modulator of alpha 7 neuronal acetylcholine receptor, 4-(5-(4-chlorophenyl)-2- methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonami de (A-867744), exhibiting unique pharmacological profile. J Pharmacol Exp Ther 330: 257-267.
27. Marks MJ, Meinerz NM, Drago J, Collins AC, (2007). Gene targeting demonstrates that alpha4 nicotinic acetylcholine receptor subunits contribute to expression of diverse [3H]epibatidine binding sites and components of biphasic 86Rb+ efflux with high and low sensitivity to stimulation by acetylcholine. Neuropharmacology 53: 390-405.
28. Marks MJ, Meinerz NM, Brown RW, Collins AC, (2010). 86Rb+ efflux mediated by alpha4beta2*-nicotinic acetylcholine receptors with high and low-sensitivity to stimulation by acetylcholine display similar agonist-induced desensitization. Biochem Pharmacol 80: 1238-1251.
29. Mattinson CE, Burmeister JJ, Quintero JE, Pomerleau F, Huettl P, Gerhardt GA, (2011). Tonic and phasic release of glutamate and acetylcholine neurotransmission in sub-regions of the rat prefrontal cortex using enzyme-based microelectrode arrays. J Neurosci Methods 202: 199-208.
30. Mazzaferro S, Benallegue N, Carbone A, Gasparri F, Vijayan R, Biggin PC, et al. (2011). Additional acetylcholine (ACh) binding site at alpha4/alpha4 interface of (alpha4beta2)2alpha4 nicotinic receptor influences agonist sensitivity. J Biol Chem 286: 31043-31054.
31. Moroni M, Zwart R, Sher E, Cassels BK, Bermudez I, (2006). alpha4beta2 nicotinic receptors with high and low acetylcholine sensitivity: pharmacology, stoichiometry, and sensitivity to long-term exposure to nicotine. Mol Pharmacol 70: 755-768.
32. Nardou R, Yamamoto S, Chazal G, Bhar A, Ferrand N, Dulac O, et al. (2011). Neuronal chloride accumulation and excitatory GABA underlie aggravation of neonatal epileptiform activities by phenobarbital. Brain 134 (Pt 4): 987-1002.
33. Nelson ME, Kuryatov A, Choi CH, Zhou Y, Lindstrom J, (2003). Alternate stoichiometries of alpha4beta2 nicotinic acetylcholine receptors. Mol Pharmacol 63: 332-341.
34. Pandya A, Yakel JL, (2011). Allosteric modulators of the alpha4beta2 subtype of neuronal nicotinic acetylcholine receptors. Biochem Pharmacol 82: 952-958.
35. Parikh V, Kozak R, Martinez V, Sarter M, (2007). Prefrontal acetylcholine release controls cue detection on multiple timescales. Neuron 56: 141-154.
36. Parikh V, Man K, Decker MW, Sarter M, (2008). Glutamatergic contributions to nicotinic acetylcholine receptor agonist-evoked cholinergic transients in the prefrontal cortex. J Neurosci 28: 3769-3780.
37. Perez XA, Bordia T, McIntosh JM, Quik M, (2010). alpha6B2* and alpha4B2* nicotinic receptors both regulate dopamine signaling with increased nigrostriatal damage: relevance to Parkinson's disease. Mol Pharmacol 78: 971-980.
38. Potter AS, Newhouse PA, Bucci DJ, (2006). Central nicotinic cholinergic systems: a role in the cognitive dysfunction in attention-deficit/hyperactivity disorder? Behav Brain Res 175: 201-211.
39. Radek RJ, Kohlhaas KL, Rueter LE, Mohler EG, (2010). Treating the cognitive deficits of schizophrenia with alpha4beta2 neuronal nicotinic receptor agonists. Curr Pharm Des 16: 309-322.
40. Rode F, Munro G, Holst D, Nielsen EO, Troelsen KB, Timmermann DB, et al. (2012). Positive allosteric modulation of alpha4beta2 nAChR agonist induced behaviour. Brain Res 1458: 67-75.
41. Sala F, Mulet J, Reddy KP, Bernal JA, Wikman P, Valor LM, et al. (2005). Potentiation of human alpha4beta2 neuronal nicotinic receptors by a Flustra foliacea metabolite. Neurosci Lett 373: 144-149.
42. Sarter M, Bruno JP, (1997). Trans-synaptic stimulation of cortical acetylcholine and enhancement of attentional functions: a rational approach for the development of cognition enhancers. Behav Brain Res 83: 7-14.
43. Sullivan JP, Donnelly-Roberts D, Briggs CA, Anderson DJ, Gopalakrishnan M, Xue IC, et al. (1997). ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy) pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties. J Pharmacol Exp Ther 283: 235-246.
44. Timmermann DB, Sandager-Nielsen K, Dyhring T, Smith M, Jacobsen AM, Nielsen EO, et al. (2012). Augmentation of cognitive function by NS9283, a stiochiometry-dependent positive allosteric modulator of alpha2- and alpha4-containing nicotinic acetylcholine receptors. Br J Pharmacol 167: 164-182.
45. Verdoorn TA, (1994). Formation of heteromeric gamma-aminobutyric acid type A receptors containing two different alpha subunits. Mol Pharmacol 45: 475-480.
46. Vinson PN, Justice JB, Jr, (1997). Effect of neostigmine on concentration and extraction fraction of acetylcholine using quantitative microdialysis. J Neurosci Methods 73: 61-67.
47. Weltzin MM, Schulte MK, (2010). Pharmacological characterization of the allosteric modulator desformylflustrabromine and its interaction with alpha4beta2 neuronal nicotinic acetylcholine receptor orthosteric ligands. J Pharmacol Exp Ther 334: 917-926.
48. A receptors is essential for benzodiazepine agonist binding. J Biol Chem 267: 1426-1429.
49. Wilens TE, Decker MW, (2007). Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition. Biochem Pharmacol 74: 1212-1223.
50. Wilens TE, Biederman J, Spencer TJ, Bostic J, Prince J, Monuteaux MC, et al. (1999). A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. Am J Psychiatry 156: 1931-1937.
51. Wilens TE, Verlinden MH, Adler LA, Wozniak PJ, West SA, (2006). ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study. Biol Psychiatry 59: 1065-1070.
52. Wilens TE, Gault LM, Childress A, Kratochvil CJ, Bensman L, Hall CM, et al. (2011). Safety and efficacy of ABT-089 in pediatric attention-deficit/ hyperactivity disorder: results from two randomized placebo-controlled clinical trials. J Am Acad Child Adolesc Psychiatry 50: 73-84. e71.
53. Zhu CZ, Chin CL, Rustay NR, Zhong C, Mikusa J, Chandran P, et al. (2011). Potentiation of analgesic efficacy but not side effects: co-administration of an alpha4beta2 neuronal nicotinic acetylcholine receptor agonist and its positive allosteric modulator in experimental models of pain in rats. Biochem Pharmacol 82: 967-976.